Gold bars to be exempt from tariffs, White House clarifies
Investing.com - Needham has raised its price target on Artivion Inc. (NYSE:AORT) to $45.00 from $32.00 while maintaining a Buy rating following the company’s strong second-quarter 2025 performance. The stock, currently trading at $32.70, has gained 29.1% over the past year and is approaching its 52-week high of $33.39.
Artivion reported second-quarter revenue and EBITDA results that exceeded consensus expectations, prompting the company to increase both its 2025 revenue and EBITDA guidance. According to InvestingPro data, the company maintains a healthy gross margin of 63.94% and has achieved revenue growth of 5.94% over the last twelve months.
The medical device company’s constant currency revenue growth improved significantly to 14.6% in the second quarter of 2025, up from 3.6% in the first quarter, driven primarily by strong performance in its On-X product line (up 24%) and stent grafts (up 22%).
Geographically, Artivion saw robust growth across all regions with North America growing 18% in constant currency, Asia Pacific increasing 15%, and EMEA (Europe, Middle East, and Africa) rising 10%.
The company’s AMDS product launch is progressing well, and Artivion is making further advances with its pipeline products including NEXUS and Arcevo, while also achieving margin improvements with gross margin up 10 basis points year-over-year and EBITDA margin increasing 290 basis points compared to the same period last year. InvestingPro analysis indicates the company maintains a GOOD overall financial health score, with net income expected to grow this year.
In other recent news, Artivion Inc. reported strong financial results for the second quarter of 2025, with revenue reaching $113 million, a 14% increase year-over-year. This performance exceeded both the consensus estimate of $108 million and various analysts’ projections, including Canaccord Genuity’s estimate of $108.7 million and Oppenheimer’s estimate of $109 million. The company also achieved an earnings per share (EPS) of $0.24, significantly surpassing the forecasted loss of $0.0033. Following these results, Canaccord Genuity raised its price target for Artivion to $41 from $35, maintaining a Buy rating. Oppenheimer also adjusted its price target to $40 from $32, affirming an Outperform rating. However, Oppenheimer later slightly reduced its target to $40 from $42, while still maintaining an Outperform rating. These developments highlight the company’s strong financial performance and the positive reception from analysts.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.